December 11, 2024 - December 13, 2024

Sai Life Sciences IPO Review & Recommendations

BP Equities (BP Wealth) and SBICAP Securities Limited have given "Apply" recommendation to Sai Life Sciences IPO. Aditya Birla Ltd, Capital Market and Dilip Davda have given "May Apply" recommendation to Sai Life Sciences IPO. Swastika Investmart Ltd has "Neutral" view about the IPO.

Sai Life Sciences IPO Review Summary from brokers and analysts

Review By	Apply	May Apply	Neutral	Avoid	Not Rated
Count	2	3	1	0	0
%	33.33	50.00	16.67	0.00	0.00

Sai Life Sciences IPO Analysis By Brokers/Analysts

Reviewer	Recommendation	Past Reviews
Aditya Birla Ltd	May Apply
BP Equities (BP Wealth)	Apply
Capital Market	May Apply
Dilip Davda	May Apply
SBICAP Securities Limited	Apply
Swastika Investmart Ltd	Neutral

Sai Life Sciences IPO Capital Market Rating

The Captial Market (CapitalMarket.com) rating for Sai Life Sciences IPO is 48. Their analysis recommends May subscribe for the IPO.

Reviewer	Rating Score	Rating
Capital Market	48	May subscribe

Sai Life Sciences IPO Review by Dilip Davda (May apply)

[Dilip Davda] The company is innovation focused CRDMO, NCE, CRO, and CMC entity, and a global player for healthcare related products development serving over 25 world’s leading pharma companies. It marked steady growth in its top lines, but the sudden boost in bottom lines for FY24 raises eyebrows. Based on FY25 annualized earnings, the issue appears aggressively priced. Well-informed/cash surplus/risk seekers may park moderate funds for long term. Read detail review...

Sai Life Sciences IPO Peer Comparison

Sai Life Sciences Limited peer comparison with similar listed entities. (As on March 28, 2024)

Company Name	EPS (Basic)	EPS (Diluted)	NAV (per share) (Rs)	P/E (x)	RoNW (%)	P/BV Ratio	Financial statements
Sai Life Sciences Limited	4.57	4.53	53.83		8.5		Consolidated
DIVI'S LABORATORIES Limited	60.27	60.27	511.21	103.04	11.79	6.72	Consolidated
Suven Pharmaceuticals Limited	11.8	11.8	94.04	109.37	14.64	7.2	Consolidated
Syngene International Ltd	12.71	12.69	105.91	73.59	11.98	6.69	Consolidated

All the financial information for listed industry peers mentioned above is consolidated and sourced from the respective company's audited financial statements for the year ended March 31, 2024, as available on the Stock Exchange websites.

The peer group's P/E ratio has been computed based on the closing market price of equity shares on BSE as of July 26, 2024, divided by the diluted EPS.

Notes:

Basic and diluted earnings/ (loss) per equity share: Basic and diluted earnings/ (loss) per equity share are computed by Indian Accounting Standard 33 notified under the Companies (Indian Accounting Standards) Rules of 2015 (as amended).
Net Asset Value per share = Restated equity attributable to owners of our Company / total number of equity shares outstanding during the period.
Return on Net Worth (%) = Restated net profit/(loss) after tax for the years/period attributable to the owners of our Company / by the Net worth as on the last date of the respective period.

Sai Life Sciences IPO Review by Members

Sai Life Sciences IPO Reviews, analysis and views by popular members. Read Sai Life Sciences Limited IPO reviews by retail investors to find recommended ipo to buy.

Post Recommendation Manage Your IPO Reviews

Sai Life Sciences IPO Review Summary by Members

Review By	Apply	May Apply	Neutral	Avoid
Count	0	0	2	1
%	0.00	0.00	66.67	33.33

Member	Review
OWAIS NAIK IPO Mentor (600+ Posts, 600+ Likes)	Neutral Company is good Can look at it post listing Valuations slightly on higher end Company's financials not showing stability Otherwise a good company \| December 12, 2024 2:59:02 PM
VIVEK LODARIYA	Avoid HIGH VALUATIONS LOW PROMOTER HOLDING \| December 9, 2024 5:33:18 PM
Atharva G	Neutral Valuations are very high Promotor holding is below 50% \| December 6, 2024 11:14:00 AM

Member

Review

OWAIS NAIK

IPO Mentor (600+ Posts, 600+ Likes)

Neutral

Company is good
Can look at it post listing
Valuations slightly on higher end
Company's financials not showing stability
Otherwise a good company

December 12, 2024 2:59:02 PM

VIVEK LODARIYA

Avoid

HIGH VALUATIONS

LOW PROMOTER HOLDING

December 9, 2024 5:33:18 PM

Atharva G

Neutral

Valuations are very high
Promotor holding is below 50%

December 6, 2024 11:14:00 AM

Post Recommendation Manage Recommendations

Note:

The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
We reserve the right to remove any objectionable post without providing a reason.

Comments

Add a public comment...